Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway.
Saved in:
| Published in: | Journal of Food and Drug Analysis |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2025
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway.
- Effect of sodium-glucose cotransporter-2 inhibitors on fracture risk in patients with type 1 diabetes receiving insulin-based therapy: a meta-analysis
- Research Progress on the Molecular Mechanism of Metformin Regulating AMPK Signaling Pathway in Inhibiting Liver Cancer
- Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling
- Acute effects of empagliflozin on open-loop baroreflex function and urine output in streptozotocin-induced type 1 diabetic rats
- Cold-inducible RNA binding protein ameliorates oxygen-glucose deprivation-induced hippocampal neuron injury through anti-apoptotic and anti-oxidative pathways
- Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high‐fat diet‐induced obese mice